Amylyx Pharmaceuticals
AMLX
171 hedge funds and large institutions have $1.59B invested in Amylyx Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 53 reducing their positions, and 36 closing their positions.
503% more call options, than puts
Call options by funds: $9.02M | Put options by funds: $1.5M
17% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 53
17% more capital invested
Capital invested by funds: $1.36B → $1.59B (+$230M)
1.02% more ownership
Funds ownership: 102.24% → 103.27% (+1%)
4% less funds holding
Funds holding: 179 → 171 (-8)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
19% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 36
Top Buyers
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$17.3M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$14.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11M |
| 4 |
Barclays
London,
United Kingdom
|
+$9.52M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$8.12M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AB
201
Amalgamated Bank
New York
| – | -$34K | -2,788 | Closed |
|
202
Daiwa Securities Group
Tokyo,
Japan
| – | -$3K | -266 | Closed |
|
|
EWM
203
Evolution Wealth Management
Fort Myers,
Florida
| – | -$1.99K | -165 | Closed |
|
|
CAIM
204
Catherine Avery Investment Management
Longboat Key,
Florida
| – | -$1.05K | -87 | Closed |
|
|
FC
205
Financial Consulate
Hunt Valley,
Maryland
| – | -$302 | -25 | Closed |
|
|
IA
206
IFP Advisors
Tampa,
Florida
| – | -$12 | -1 | Closed |
|
|
C
207
Covestor
London,
United Kingdom
| – | +$127 | +9 | New |
|
AMLX Hedge Fund Activity: Q1 2026 in Review
171 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2026, worth a combined $1.59B — up 17% from $1.36B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of AMLX and 29 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 62 added.
The largest buyer was Siren LLC, opening a new position worth an estimated $17.3M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $6.37M sold.
- 171 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2026, down from 179 in Q4 2025.
- Funds reported $1.59B of Amylyx Pharmaceuticals stock for Q1 2026, up 17% quarter-over-quarter.
- 29 funds opened new Amylyx Pharmaceuticals positions in Q1 2026 and 36 closed out, a net change of -7 holders.
- The largest Amylyx Pharmaceuticals buyer in Q1 2026 was Siren LLC, an estimated $17.3M added.
- The largest Amylyx Pharmaceuticals seller in Q1 2026 was Sofinnova Investments, an estimated $6.37M sold.
Based on aggregated 13F filings for Q1 2026.